Targeting dormancy in acute myeloid leukaemia
Acute myeloid leukaemia (AML) represents the poorest survival rate of all leukaemias, and the majority of patients who do achieve remission relapse within 3 years. Relapse is attributed to the presence of quiescent leukaemia initiating cells (LICs) which evade standard-of-care chemotherapy that targ...
| Main Author: | |
|---|---|
| Format: | Thesis (University of Nottingham only) |
| Language: | English |
| Published: |
2023
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/76442/ |